Ibandronic Acid Teva
Ibandronic acid 50 mg – Film-coated tablet for reduction of bone complications
Quick Facts about Ibandronic Acid Teva
Key Takeaways
- Take on an empty stomach: Swallow with a full glass of plain water at least 6 hours after the last food or drink, and wait at least 60 minutes before eating
- Stay upright after taking: Do not lie down for at least 60 minutes after swallowing the tablet to prevent esophageal irritation
- Reduces bone complications: Clinically proven to reduce fractures, bone pain, and skeletal events in breast cancer patients with bone metastases
- Dental care is important: Inform your dentist that you are taking a bisphosphonate, as there is a small risk of osteonecrosis of the jaw
- Do not take with other medicines: Calcium, antacids, and mineral supplements significantly reduce absorption – maintain a 6-hour gap
What Is Ibandronic Acid Teva and What Is It Used For?
Ibandronic Acid Teva is a bisphosphonate medication containing ibandronic acid 50 mg as film-coated tablets. It is prescribed to reduce the risk of skeletal-related events (such as bone fractures, bone complications requiring radiotherapy, or surgery) in patients with breast cancer that has spread to the bones (bone metastases).
Ibandronic acid belongs to a group of medicines known as bisphosphonates. These drugs target the bones specifically, working to slow down and prevent the destructive processes that occur when cancer cells spread to the skeleton. In breast cancer, bone metastases are one of the most common sites of disease spread, affecting up to 70% of patients with advanced breast cancer. When cancer cells settle in the bones, they disrupt the normal balance between bone formation and bone breakdown, leading to excessive bone resorption, weakened skeletal structure, and painful complications.
The medication works by binding to the mineral component of bone (hydroxyapatite) and inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue. By suppressing osteoclast-mediated bone resorption, ibandronic acid helps preserve bone integrity, reduces the release of calcium from bones into the bloodstream, and decreases the incidence of skeletal complications. Clinical trials have demonstrated that daily oral ibandronic acid 50 mg significantly reduces the rate of skeletal-related events compared with placebo in patients with bone metastases from breast cancer.
In addition to reducing fractures and the need for radiation therapy to bone, ibandronic acid has been shown to reduce bone pain in patients with skeletal metastases. The oral formulation offers a convenient alternative to intravenous bisphosphonate therapy, allowing patients to take their medication at home rather than requiring hospital visits for infusions. However, the oral route requires strict adherence to specific dosing instructions to ensure adequate absorption and to minimize the risk of gastrointestinal side effects.
Ibandronic Acid Teva 50 mg tablets are specifically indicated for bone metastases in breast cancer. Different strengths and formulations of ibandronic acid (such as 150 mg monthly tablets or intravenous formulations) may be used for other conditions such as postmenopausal osteoporosis. Do not interchange formulations without consulting your prescriber.
How does ibandronic acid work in the body?
After oral administration, ibandronic acid is absorbed from the upper gastrointestinal tract. Its bioavailability is relatively low (approximately 0.6%) and is significantly reduced by food, drinks other than plain water, and medications containing divalent cations such as calcium, magnesium, iron, or aluminium. This is why strict fasting conditions are required when taking the medication.
Once absorbed, ibandronic acid rapidly distributes to bone tissue, where it binds tightly to hydroxyapatite crystals on the bone surface. At the cellular level, it is taken up by osteoclasts during the bone resorption process. Inside the osteoclast, ibandronic acid inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which is essential for osteoclast function and survival. This leads to disruption of the osteoclast cytoskeleton, loss of the ruffled border needed for bone resorption, and ultimately apoptosis (programmed cell death) of the osteoclast.
The portion of ibandronic acid that is not taken up by bone is eliminated unchanged by the kidneys. The drug has a very long terminal half-life in bone tissue, reflecting its tight binding to the mineral matrix. This prolonged skeletal retention means that the therapeutic effects of the drug persist long after circulating levels have declined.
What Should You Know Before Taking Ibandronic Acid Teva?
Do not take Ibandronic Acid Teva if you are allergic to ibandronic acid or any of the excipients, have abnormalities of the esophagus, cannot stand or sit upright for at least 60 minutes, or have low blood calcium (hypocalcemia). Inform your doctor about all medical conditions, especially kidney problems, dental issues, and other medications you are taking.
Contraindications
You must not take Ibandronic Acid Teva if any of the following apply to you:
- Hypersensitivity: You are allergic to ibandronic acid or any of the other ingredients in the tablet
- Esophageal abnormalities: You have conditions that delay esophageal emptying, such as stricture or achalasia
- Inability to stand or sit upright: You cannot remain upright (sitting or standing) for at least 60 minutes after taking the tablet
- Hypocalcemia: You have low blood calcium levels that have not been corrected
- Severe kidney impairment: You have severely reduced kidney function (creatinine clearance below 30 ml/min)
Warnings and Precautions
Before starting treatment with Ibandronic Acid Teva, tell your doctor if you have any of the following conditions or risk factors:
Gastrointestinal effects: Oral bisphosphonates can cause local irritation of the upper gastrointestinal mucosa. Patients with active upper gastrointestinal problems (such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers) should use this medicine with caution. Esophageal adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosions have been reported. To minimize the risk, patients must follow the dosing instructions carefully.
Osteonecrosis of the jaw (ONJ): This is a rare but serious condition in which the bone tissue in the jaw fails to heal, typically following dental surgery or trauma. Risk factors include cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, anti-angiogenic agents), poor oral hygiene, dental procedures (especially tooth extractions), and co-morbidities such as dental disease, anaemia, coagulopathy, or infection. A dental examination with appropriate preventive dentistry should be considered before starting bisphosphonate treatment. Patients should be advised to maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling.
Atypical femoral fractures: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment. These fractures may occur with minimal or no trauma in the thigh or groin area. Any patient who presents with thigh or groin pain should be evaluated for an incomplete femoral fracture. Discontinuation of bisphosphonate therapy should be considered on an individual basis.
Kidney function: Ibandronic acid is excreted by the kidneys. Your doctor should monitor your kidney function periodically, especially if you have pre-existing renal impairment or are taking other medications that may affect kidney function. Dose adjustments are not required for mild to moderate renal impairment, but the drug should not be used in patients with severe renal impairment.
Hypocalcemia: Pre-existing hypocalcemia and other disturbances of bone and mineral metabolism must be effectively treated before starting therapy. Adequate intake of calcium and vitamin D is important for all patients.
Failure to follow the dosing instructions may increase the risk of esophageal adverse reactions. Patients should be specifically instructed to swallow the tablet with a full glass of plain water (not mineral water), while in an upright position, and not to lie down for at least 60 minutes after taking the dose. Patients should not chew or suck the tablet due to the potential for oropharyngeal ulceration. If symptoms of esophageal irritation occur (such as new or worsening difficulty swallowing, pain on swallowing, or chest pain), stop taking the medication and consult your doctor.
Pregnancy and Breastfeeding
Ibandronic Acid Teva is not intended for use in women of childbearing potential under normal circumstances, as it is primarily prescribed for bone metastases in breast cancer. However, it is important to note the following:
Pregnancy: There are no adequate data on the use of ibandronic acid in pregnant women. Animal studies have shown reproductive toxicity. Bisphosphonates are incorporated into the bone matrix from where they are gradually released over years. The amount of bisphosphonate incorporated into adult bone, and hence the potential for release back into the systemic circulation, is directly related to the cumulative dose and duration of treatment. Ibandronic acid should not be used during pregnancy unless the clinical condition of the woman requires treatment and the potential benefit outweighs the risk to the fetus.
Breastfeeding: It is not known whether ibandronic acid is excreted in human breast milk. Studies in lactating rats showed low levels of ibandronic acid in milk. A decision must be made whether to discontinue breast-feeding or to discontinue the therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
How Does Ibandronic Acid Teva Interact with Other Drugs?
Calcium supplements, antacids, and mineral-containing products significantly reduce ibandronic acid absorption. NSAIDs may increase the risk of gastrointestinal irritation. Aminoglycoside antibiotics can enhance the calcium-lowering effect. Maintain a 6-hour gap between ibandronic acid and other oral medications to ensure proper absorption.
Drug interactions with ibandronic acid are primarily related to its absorption characteristics and its effects on calcium metabolism. Because ibandronic acid has very low oral bioavailability and its absorption is highly sensitive to the presence of food and other substances in the gastrointestinal tract, the timing of administration relative to other medications is critically important.
Major Interactions
The following interactions are considered clinically significant and require careful management:
| Interacting Drug | Effect | Management |
|---|---|---|
| Calcium supplements | Significantly reduces absorption of ibandronic acid through chelation | Take calcium supplements at least 6 hours after ibandronic acid |
| Antacids (Al, Mg, Ca-containing) | Severely reduces bioavailability through divalent cation binding | Take antacids at least 6 hours after ibandronic acid |
| Iron supplements | Reduces absorption through chelation with divalent cations | Take iron supplements at least 6 hours after ibandronic acid |
| Aminoglycoside antibiotics | May enhance the calcium-lowering effect, increasing risk of hypocalcemia | Monitor serum calcium closely during concomitant use |
Minor Interactions
The following interactions are generally less severe but should be noted:
| Interacting Drug | Effect | Management |
|---|---|---|
| NSAIDs (e.g. ibuprofen, naproxen) | May increase risk of gastrointestinal irritation and ulceration | Use with caution; report any GI symptoms promptly |
| Aspirin | May increase risk of upper GI adverse events | Use with caution, particularly at higher analgesic doses |
| H2-receptor antagonists / PPIs | No significant pharmacokinetic interaction demonstrated | Can be used concurrently; take ibandronic acid first on an empty stomach |
| Chemotherapy agents | No direct pharmacokinetic interaction, but may compound renal effects | Monitor kidney function more frequently during combination therapy |
Ibandronic acid is not metabolized by cytochrome P450 enzymes and does not inhibit or induce hepatic CYP450 enzymes. Therefore, metabolic drug interactions are unlikely. The drug is eliminated solely through renal excretion and does not undergo biotransformation. In clinical studies, no interactions were observed with tamoxifen or hormone replacement therapy (estrogen) when co-administered with ibandronic acid.
What Is the Correct Dosage of Ibandronic Acid Teva?
The recommended dose is one 50 mg tablet taken once daily on an empty stomach. Swallow whole with a full glass of plain water (200 ml) while sitting or standing upright. Do not eat, drink (except water), or take other medications for at least 60 minutes after the dose.
Adults
Standard Dosing for Bone Metastases (Breast Cancer)
Dose: 50 mg (one tablet) once daily
Administration: Take on an empty stomach after an overnight fast (at least 6 hours after the last food, drink, or other oral medication). Swallow whole with a full glass (200 ml) of plain water only – not mineral water, coffee, tea, juice, or milk. Remain upright (sitting or standing) for at least 60 minutes after taking the tablet. Do not eat, drink anything other than plain water, or take other oral medications for at least 60 minutes.
Duration: Treatment continues as long as clinically indicated. Your oncologist will assess the ongoing benefit of therapy at regular intervals.
- Take the tablet first thing in the morning, before eating or drinking anything
- While sitting or standing upright, swallow the tablet whole with a full glass (200 ml) of plain water
- Do not chew, crush, or suck the tablet
- Do not lie down for at least 60 minutes
- Do not eat, drink (except plain water), or take other oral medicines for at least 60 minutes after the tablet
- After 60 minutes, you may eat your breakfast and take other medicines normally
Children
Ibandronic Acid Teva is not recommended for use in children and adolescents below 18 years of age. There is no relevant indication for use in the paediatric population for this formulation. Safety and efficacy in children have not been established.
Elderly
No dose adjustment is required for elderly patients. Age alone does not require any modification of the dosing regimen. However, elderly patients may be more susceptible to gastrointestinal side effects and should be carefully counselled on the importance of following the dosing instructions precisely. Kidney function should be assessed before initiation and monitored periodically, as age-related decline in renal function may affect drug clearance.
Renal Impairment
No dose adjustment is needed for patients with mild to moderate renal impairment (creatinine clearance above 30 ml/min). Ibandronic Acid Teva should not be used in patients with severe renal impairment (creatinine clearance below 30 ml/min) due to limited clinical experience and the risk of drug accumulation.
Missed Dose
If you miss a dose, take it the next morning as soon as you remember, following the standard dosing instructions (empty stomach, full glass of water, remain upright for 60 minutes). Do not take two tablets on the same day to make up for a missed dose. Then return to your regular daily schedule. If you are unsure about what to do, contact your doctor or pharmacist for advice.
Overdose
No specific information is available on the treatment of overdose with Ibandronic Acid Teva. Based on the pharmacology of the drug class, overdose may result in upper gastrointestinal adverse events (such as upset stomach, heartburn, esophagitis, gastritis, or ulcer) and hypocalcemia. Milk or antacids should be given to bind the drug and reduce absorption. Due to the risk of esophageal irritation, vomiting should not be induced, and the patient should remain fully upright. Standard supportive medical management, including correction of hypocalcemia with intravenous calcium gluconate if necessary, should be initiated as clinically indicated. Seek emergency medical attention if overdose is suspected.
What Are the Side Effects of Ibandronic Acid Teva?
Common side effects include nausea, diarrhea, dyspepsia, abdominal pain, musculoskeletal pain, fatigue, and headache. Uncommon but serious side effects include esophagitis, osteonecrosis of the jaw, and atypical femoral fractures. Most gastrointestinal effects are mild and tend to improve with continued treatment.
Like all medicines, Ibandronic Acid Teva can cause side effects, although not everybody gets them. The following information is based on clinical trial data and post-marketing surveillance reports. Side effects are classified by frequency according to the standard convention used by the European Medicines Agency (EMA).
Most side effects associated with oral ibandronic acid are related to the gastrointestinal tract, reflecting the local irritant properties of the drug on the upper GI mucosa. Musculoskeletal symptoms are also common and are a class effect of bisphosphonates. Most adverse reactions are mild to moderate in severity and tend to diminish with continued use.
Common
- Nausea
- Diarrhea
- Dyspepsia (indigestion)
- Abdominal pain
- Musculoskeletal pain (bone, muscle, or joint pain)
- Fatigue and asthenia (tiredness, weakness)
- Headache
- Hypercalcemia (elevated blood calcium, in context of underlying disease)
- Skin rash
- Flu-like symptoms (fever, chills, malaise)
Uncommon
- Esophagitis (inflammation of the esophagus)
- Esophageal ulcers or erosions
- Dysphagia (difficulty swallowing)
- Vomiting
- Flatulence
- Gastritis
- Dizziness
- Hypocalcemia (low blood calcium)
- Itching (pruritus)
- Urticaria (hives)
Rare
- Osteonecrosis of the jaw (ONJ)
- Atypical femoral fractures
- Esophageal stricture
- Severe skin reactions (e.g. Stevens-Johnson syndrome)
- Ocular inflammation (uveitis, scleritis, episcleritis)
- Anaphylactic reaction or angioedema
- Hepatitis or liver function abnormalities
- New or worsening difficulty swallowing, pain on swallowing, or retrosternal (behind the breastbone) pain
- Jaw pain, swelling, numbness, or loose teeth – may indicate osteonecrosis of the jaw
- New pain in the thigh, hip, or groin area – may indicate atypical femoral fracture
- Signs of severe allergic reaction: skin rash, swelling of the face, lips, tongue, or throat, difficulty breathing
- Eye pain, redness, or blurred vision
Stop taking the medication and contact your doctor or seek emergency care if any of these symptoms occur.
Musculoskeletal effects
Bone, joint, and muscle pain are commonly reported with bisphosphonate therapy and represent a class effect. These symptoms may occur within days, months, or years after starting treatment. Some patients experience severe musculoskeletal pain that may be incapacitating. In most cases, symptoms resolve partially or completely after discontinuation of the drug. If severe musculoskeletal pain develops, your doctor may recommend temporary or permanent discontinuation of Ibandronic Acid Teva.
Long-term risks
Prolonged bisphosphonate therapy has been associated with two rare but serious skeletal complications: osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The risk increases with the duration of exposure. Your doctor will periodically reassess the need for continued treatment, weighing the benefits of ongoing therapy against these potential risks. Good oral hygiene and regular dental examinations can help reduce the risk of ONJ. Any new thigh or groin pain should be promptly evaluated.
How Should You Store Ibandronic Acid Teva?
Store Ibandronic Acid Teva at room temperature below 25°C (77°F) in the original packaging to protect from moisture. Keep out of sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their efficacy and safety. Follow these guidelines for storing Ibandronic Acid Teva:
- Temperature: Store below 25°C (77°F). Do not freeze.
- Moisture protection: Keep the tablets in their original blister packaging until you are ready to take them. The blister packaging protects against moisture that could degrade the tablet.
- Light: No special precautions are required regarding light exposure, but storing in the original carton is recommended.
- Children: Keep this medicine out of the sight and reach of children. Store in a secure location.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister. The expiry date refers to the last day of that month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment and prevent accidental ingestion by others.
What Does Ibandronic Acid Teva Contain?
Each film-coated tablet contains 50 mg of ibandronic acid (as ibandronate sodium monohydrate). Excipients include lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate, and a film-coating containing hypromellose, titanium dioxide, and macrogol.
Active ingredient
Each film-coated tablet contains 50 mg ibandronic acid (as ibandronate sodium monohydrate, equivalent to 56.25 mg ibandronate sodium monohydrate). Ibandronic acid has the molecular formula C5H13NO7P2 and belongs chemically to the nitrogen-containing bisphosphonate group. It is a white to off-white crystalline powder, freely soluble in water.
Inactive ingredients (excipients)
The tablet core and film-coating contain the following inactive ingredients:
- Tablet core: Lactose monohydrate, povidone K25, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate
- Film-coating: Hypromellose (HPMC), titanium dioxide (E171), macrogol 400
Lactose: This product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Appearance
Ibandronic Acid Teva 50 mg film-coated tablets are white to off-white, oblong-shaped tablets, scored on one side. They are packaged in PVC/PVDC/aluminium blister packs.
Frequently Asked Questions
Ibandronic Acid Teva 50 mg tablets are used to reduce skeletal events (bone fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. It belongs to the bisphosphonate class of medications and works by inhibiting osteoclast-mediated bone resorption, thereby preserving bone integrity and reducing painful complications. This specific formulation and strength is indicated for bone metastases rather than osteoporosis prevention.
Take one 50 mg tablet once daily, first thing in the morning on an empty stomach. Swallow the tablet whole with a full glass (200 ml) of plain water – not mineral water, coffee, tea, juice, or milk. You must sit or stand upright while taking the tablet and remain upright for at least 60 minutes afterwards. Do not chew, crush, or suck the tablet. Wait at least 60 minutes before eating, drinking anything other than plain water, or taking other medications.
The most common side effects include gastrointestinal symptoms such as nausea, diarrhea, indigestion (dyspepsia), and abdominal pain. Musculoskeletal pain (affecting bones, muscles, or joints), fatigue, headache, and flu-like symptoms are also common. Most of these effects are mild to moderate and tend to improve with continued treatment. Following the dosing instructions carefully, particularly remaining upright after taking the tablet, helps minimize gastrointestinal side effects.
Yes, calcium supplements are often recommended alongside bisphosphonate therapy to ensure adequate calcium intake. However, timing is crucial. Calcium supplements, antacids, and other mineral-containing products significantly reduce the absorption of ibandronic acid. You must wait at least 60 minutes (ideally 6 hours) after taking your ibandronic acid tablet before consuming any calcium supplements, antacids, or mineral-containing products. Many patients find it easiest to take their calcium supplements in the evening, well separated from their morning ibandronic acid dose.
Osteonecrosis of the jaw (ONJ) is a rare condition where bone tissue in the jaw fails to heal, typically after dental surgery such as tooth extraction. To reduce your risk: maintain excellent oral hygiene with regular brushing and flossing; attend routine dental check-ups; inform your dentist that you are taking a bisphosphonate before any dental procedures; complete any necessary dental work before starting bisphosphonate therapy if possible; and report any jaw pain, swelling, numbness, or loose teeth to your doctor promptly.
The duration of treatment is determined by your oncologist based on your individual clinical situation, including the extent of bone metastases, your response to treatment, and overall health status. Treatment typically continues for as long as it provides clinical benefit in reducing skeletal events. Your doctor will regularly reassess whether continued treatment is appropriate, balancing the benefits against the potential risks of long-term bisphosphonate use such as osteonecrosis of the jaw and atypical femoral fractures.
References
This article is based on the following peer-reviewed sources and regulatory guidelines:
- European Medicines Agency (EMA). Ibandronic Acid Teva – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu
- Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology. 2003;14(9):1399-1405.
- Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. The Lancet Oncology. 2014;15(1):114-122.
- Coleman RE, Croucher PI, Padhani AR, et al. Bone metastases. Nature Reviews Disease Primers. 2020;6(1):83.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of Bone and Mineral Research. 2015;30(1):3-23.
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. 2014;29(1):1-23.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- British National Formulary (BNF). Ibandronic acid. Available at: bnf.nice.org.uk
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer (Version 4.2024).
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Bone metastases from solid tumours. Annals of Oncology. 2020;31(10):1381-1390.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specializations in clinical pharmacology, oncology, and evidence-based medicine.
Medical Writing
iMedic Medical Editorial Team – Specialists in clinical pharmacology and pharmaceutical medicine with extensive experience in drug information and patient education.
Medical Review
iMedic Medical Review Board – Independent panel of board-certified physicians who verify accuracy against EMA SmPC, FDA prescribing information, BNF, and peer-reviewed literature.
Evidence standard: Level 1A – Based on systematic reviews and meta-analyses of randomized controlled trials. All content follows the GRADE evidence framework and is reviewed according to guidelines from EMA, WHO, FDA, BNF, and ESMO.